SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-011064
Filing Date
2021-08-10
Accepted
2021-08-10 07:31:09
Documents
59
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q sgtx-20210630x10q.htm   iXBRL 10-Q 1709892
2 EX-10.1 sgtx-20210630xex10d1.htm EX-10.1 62819
3 EX-31.1 sgtx-20210630xex31d1.htm EX-31.1 36211
4 EX-32.1 sgtx-20210630xex32d1.htm EX-32.1 10202
  Complete submission text file 0001558370-21-011064.txt   5545508

Data Files

Seq Description Document Type Size
5 EX-101.SCH sgtx-20210630.xsd EX-101.SCH 36838
6 EX-101.CAL sgtx-20210630_cal.xml EX-101.CAL 41572
7 EX-101.DEF sgtx-20210630_def.xml EX-101.DEF 102172
8 EX-101.LAB sgtx-20210630_lab.xml EX-101.LAB 360398
9 EX-101.PRE sgtx-20210630_pre.xml EX-101.PRE 251572
10 EXTRACTED XBRL INSTANCE DOCUMENT sgtx-20210630x10q_htm.xml XML 753299
Mailing Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 617-336-7540
Sigilon Therapeutics, Inc. (Filer) CIK: 0001821323 (see all company filings)

IRS No.: 474005543 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39746 | Film No.: 211158431
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences